Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Sharmin, S, Lefort, M, Andersen, JB, Leray, E, Horakova, D, Havrdova, EK, Alroughani, R, Izquierdo, G, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand'Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sellebjerg, FT, Soerensen, PS, Jensen, MB, Frederiksen, JL, Bramow, S, Mathiesen, HK, Schreiber, KI, Magyari, M & Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, 'Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts', CNS Drugs, vol. 35, no. 11, pp. 1217-1232. https://doi.org/10.1007/s40263-021-00860-7

APA

Sharmin, S., Lefort, M., Andersen, J. B., Leray, E., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand'Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., ... Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators (2021). Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 35(11), 1217-1232. https://doi.org/10.1007/s40263-021-00860-7

CBE

Sharmin S, Lefort M, Andersen JB, Leray E, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, Sellebjerg FT, Soerensen PS, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Magyari M, Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators. 2021. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs. 35(11):1217-1232. https://doi.org/10.1007/s40263-021-00860-7

MLA

Vancouver

Author

Sharmin, Sifat ; Lefort, Mathilde ; Andersen, Johanna Balslev ; Leray, Emmanuelle ; Horakova, Dana ; Havrdova, Eva Kubala ; Alroughani, Raed ; Izquierdo, Guillermo ; Ozakbas, Serkan ; Patti, Francesco ; Onofrj, Marco ; Lugaresi, Alessandra ; Terzi, Murat ; Grammond, Pierre ; Grand'Maison, Francois ; Yamout, Bassem ; Prat, Alexandre ; Girard, Marc ; Duquette, Pierre ; Boz, Cavit ; Trojano, Maria ; McCombe, Pamela ; Slee, Mark ; Lechner-Scott, Jeannette ; Turkoglu, Recai ; Sola, Patrizia ; Ferraro, Diana ; Granella, Franco ; Prevost, Julie ; Maimone, Davide ; Skibina, Olga ; Buzzard, Katherine ; Van der Walt, Anneke ; Van Wijmeersch, Bart ; Csepany, Tunde ; Spitaleri, Daniele ; Vucic, Steve ; Casey, Romain ; Debouverie, Marc ; Edan, Gilles ; Ciron, Jonathan ; Ruet, Aurélie ; Sellebjerg, Finn Thorup ; Soerensen, Per Soelberg ; Jensen, Michael Broksgaard ; Frederiksen, Jette Lautrup ; Bramow, Stephan ; Mathiesen, Henrik Kahr ; Schreiber, Karen Ingrid ; Magyari, Melinda ; Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators. / Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts. In: CNS Drugs. 2021 ; Vol. 35, No. 11. pp. 1217-1232.

Bibtex

@article{83fcf5055a1d422681467ecff939a584,
title = "Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts",
abstract = "INTRODUCTION: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined.OBJECTIVE: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest.METHODS: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients' sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed with weighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score.RESULTS: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15-41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65-0.88); in those aged ≤ 38 years (0.64; 0.54-0.76); in those with disease duration ≤ 7 years (0.63; 0.53-0.76); in those with EDSS score < 4 (0.75; 0.64-0.88), < 6 (0.80; 0.70-0.91), and ≥ 6 (0.52; 0.31-0.86); and in patients with pre-baseline relapses (0.74; 0.64-0.86). A higher probability of confirmed disability improvement on natalizumab versus fingolimod (hazard ratio [HR]; 95% CI) was observed among women (1.36; 1.10-1.66); those aged > 38 years (1.34; 1.04-1.73); those with disease duration > 7 years (1.33; 1.01-1.74); those with EDSS score < 6 (1.21; 1.01-1.46) and ≥ 6 (1.93; 1.11-3.34); and patients with no new MRI lesion (1.73; 1.19-2.51).CONCLUSIONS: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.",
author = "Sifat Sharmin and Mathilde Lefort and Andersen, {Johanna Balslev} and Emmanuelle Leray and Dana Horakova and Havrdova, {Eva Kubala} and Raed Alroughani and Guillermo Izquierdo and Serkan Ozakbas and Francesco Patti and Marco Onofrj and Alessandra Lugaresi and Murat Terzi and Pierre Grammond and Francois Grand'Maison and Bassem Yamout and Alexandre Prat and Marc Girard and Pierre Duquette and Cavit Boz and Maria Trojano and Pamela McCombe and Mark Slee and Jeannette Lechner-Scott and Recai Turkoglu and Patrizia Sola and Diana Ferraro and Franco Granella and Julie Prevost and Davide Maimone and Olga Skibina and Katherine Buzzard and {Van der Walt}, Anneke and {Van Wijmeersch}, Bart and Tunde Csepany and Daniele Spitaleri and Steve Vucic and Romain Casey and Marc Debouverie and Gilles Edan and Jonathan Ciron and Aur{\'e}lie Ruet and Sellebjerg, {Finn Thorup} and Soerensen, {Per Soelberg} and Jensen, {Michael Broksgaard} and Frederiksen, {Jette Lautrup} and Stephan Bramow and Mathiesen, {Henrik Kahr} and Schreiber, {Karen Ingrid} and Melinda Magyari and {Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators}",
note = "{\textcopyright} 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.",
year = "2021",
month = nov,
doi = "10.1007/s40263-021-00860-7",
language = "English",
volume = "35",
pages = "1217--1232",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "11",

}

RIS

TY - JOUR

T1 - Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis

T2 - A Subgroup Analysis From Three International Cohorts

AU - Sharmin, Sifat

AU - Lefort, Mathilde

AU - Andersen, Johanna Balslev

AU - Leray, Emmanuelle

AU - Horakova, Dana

AU - Havrdova, Eva Kubala

AU - Alroughani, Raed

AU - Izquierdo, Guillermo

AU - Ozakbas, Serkan

AU - Patti, Francesco

AU - Onofrj, Marco

AU - Lugaresi, Alessandra

AU - Terzi, Murat

AU - Grammond, Pierre

AU - Grand'Maison, Francois

AU - Yamout, Bassem

AU - Prat, Alexandre

AU - Girard, Marc

AU - Duquette, Pierre

AU - Boz, Cavit

AU - Trojano, Maria

AU - McCombe, Pamela

AU - Slee, Mark

AU - Lechner-Scott, Jeannette

AU - Turkoglu, Recai

AU - Sola, Patrizia

AU - Ferraro, Diana

AU - Granella, Franco

AU - Prevost, Julie

AU - Maimone, Davide

AU - Skibina, Olga

AU - Buzzard, Katherine

AU - Van der Walt, Anneke

AU - Van Wijmeersch, Bart

AU - Csepany, Tunde

AU - Spitaleri, Daniele

AU - Vucic, Steve

AU - Casey, Romain

AU - Debouverie, Marc

AU - Edan, Gilles

AU - Ciron, Jonathan

AU - Ruet, Aurélie

AU - Sellebjerg, Finn Thorup

AU - Soerensen, Per Soelberg

AU - Jensen, Michael Broksgaard

AU - Frederiksen, Jette Lautrup

AU - Bramow, Stephan

AU - Mathiesen, Henrik Kahr

AU - Schreiber, Karen Ingrid

AU - Magyari, Melinda

AU - Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators

N1 - © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

PY - 2021/11

Y1 - 2021/11

N2 - INTRODUCTION: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined.OBJECTIVE: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest.METHODS: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients' sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed with weighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score.RESULTS: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15-41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65-0.88); in those aged ≤ 38 years (0.64; 0.54-0.76); in those with disease duration ≤ 7 years (0.63; 0.53-0.76); in those with EDSS score < 4 (0.75; 0.64-0.88), < 6 (0.80; 0.70-0.91), and ≥ 6 (0.52; 0.31-0.86); and in patients with pre-baseline relapses (0.74; 0.64-0.86). A higher probability of confirmed disability improvement on natalizumab versus fingolimod (hazard ratio [HR]; 95% CI) was observed among women (1.36; 1.10-1.66); those aged > 38 years (1.34; 1.04-1.73); those with disease duration > 7 years (1.33; 1.01-1.74); those with EDSS score < 6 (1.21; 1.01-1.46) and ≥ 6 (1.93; 1.11-3.34); and patients with no new MRI lesion (1.73; 1.19-2.51).CONCLUSIONS: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.

AB - INTRODUCTION: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined.OBJECTIVE: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest.METHODS: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients' sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed with weighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score.RESULTS: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15-41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65-0.88); in those aged ≤ 38 years (0.64; 0.54-0.76); in those with disease duration ≤ 7 years (0.63; 0.53-0.76); in those with EDSS score < 4 (0.75; 0.64-0.88), < 6 (0.80; 0.70-0.91), and ≥ 6 (0.52; 0.31-0.86); and in patients with pre-baseline relapses (0.74; 0.64-0.86). A higher probability of confirmed disability improvement on natalizumab versus fingolimod (hazard ratio [HR]; 95% CI) was observed among women (1.36; 1.10-1.66); those aged > 38 years (1.34; 1.04-1.73); those with disease duration > 7 years (1.33; 1.01-1.74); those with EDSS score < 6 (1.21; 1.01-1.46) and ≥ 6 (1.93; 1.11-3.34); and patients with no new MRI lesion (1.73; 1.19-2.51).CONCLUSIONS: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.

UR - http://www.scopus.com/inward/record.url?scp=85115657202&partnerID=8YFLogxK

U2 - 10.1007/s40263-021-00860-7

DO - 10.1007/s40263-021-00860-7

M3 - Journal article

C2 - 34536228

VL - 35

SP - 1217

EP - 1232

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 11

ER -

ID: 67842554